Fentanyl
Complex Regional Pain Syndrome
Janssen Pharmaceutical K.K.Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Complex Regional Pain Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lidocaine Endo USA Inc., a Keenova Therapeutics Company | Phase 4 | BB |
Ibuprofen Amgen | Phase 3 | BB |
Gabapentin Endo USA Inc., a Keenova Therapeutics Company | Phase 4 | BB |
Naltrexone Hospital for Special Surgery, New York | Phase 4 | BB |
Axs-02 Axsome Therapeutics, Inc. | Phase 3 | B |
View all 19 →
Same molecule, other indications
Fentanyl is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →